• Cabazitaxel (XRP6258): Technical Guidance for Resistant Mode

  2026-07-06

  Cabazitaxel (XRP6258) is a semi-synthetic taxane formulated to disrupt microtubule dynamics in cancer research models that exhibit resistance to conventional taxanes. It is specifically suited for use in DMSO- or ethanol-based workflows and should not be used in aqueous systems or stored in solution long term due to solubility and stability constraints.

• Low-Affinity N-Type Calcium Channel Blockade by v-Agatoxin-I

  2026-07-06

  Sidach and Mintz (2000) reveal that the spider toxin v-Agatoxin-IVA, traditionally regarded as a highly selective P-type calcium channel blocker, also exerts low-affinity inhibition of N-type channels in mammalian neurons. This nuanced pharmacological profile challenges canonical channel classification and has far-reaching implications for experimental design in neurophysiology and neuroprotective agent research.

• RSL3: A Precision Glutathione Peroxidase 4 Inhibitor for Fer

  2026-07-05

  (1S,3R)-RSL3 is a highly selective glutathione peroxidase 4 inhibitor that induces ferroptosis via lipid peroxidation. Its action enables robust, caspase-independent cell death in RAS-driven cancers, demonstrating synthetic lethality and translational potential in preclinical oncology research.

• Morin: Applied Protocols for Antioxidant and Ion Probe Resea

  2026-07-04

  Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one) bridges antioxidant and bioanalytical workflows with unique dual activity as a mitochondrial modulator and fluorescent aluminum ion probe. This guide delivers actionable, evidence-backed strategies for maximizing Morin’s performance in metabolic, neuroprotective, and metal detection assays.

• Parathyroid Hormone (1-34) (Human): Applied Workflows & Opti

  2026-07-03

  Parathyroid hormone (1-34) (human) empowers advanced bone and kidney disease modeling with reproducible, high-fidelity results. This guide demystifies workflow setup, protocol refinements, and troubleshooting, leveraging recent breakthroughs in spatially patterned kidney assembloids and APExBIO’s gold-standard peptide fragment.

• Pregnenolone Carbonitrile: Precision for CYP3A and Neuroprot

  2026-07-03

  Explore how Pregnenolone Carbonitrile (PCN) is redefining the frontiers of translational research by uniquely bridging hepatic detoxification and neuroprotective mechanisms. This article synthesizes mechanistic insight, experimental guidance, and practical perspectives for translational scientists striving to unravel the dual PXR- and glucocorticoid receptor-dependent actions of PCN. Strategic protocol recommendations, competitive landscape analysis, and a vision for the next decade of xenobiotic metabolism and antifibrotic research are presented, grounded in recent evidence and workflow-ready expertise.

• Methoxy-X04: High-Affinity Fluorescent Amyloid Beta Probe

  2026-07-02

  Methoxy-X04 is a brain-permeable, high-affinity fluorescent amyloid beta probe enabling rapid, selective visualization of amyloid pathology in Alzheimer's disease models. Its nanomolar binding to Aβ fibrils and capacity for in vivo plaque imaging underpin its value in neurodegenerative research and workflow reproducibility.

• SU 5402: Precision FGFR/VEGFR Inhibition and Human Neuron Mo

  2026-07-02

  Explore the multifaceted research utility of SU 5402, a potent receptor tyrosine kinase inhibitor. This article uniquely examines SU 5402’s mechanistic actions and its integration with advanced human sensory neuron models, providing new perspectives for multiple myeloma and neurovirology research.

• Applied Workflows with 2-(4,5,6,7-tetrabromo...) Acetic Acid

  2026-07-01

  2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid empowers researchers to dissect kinase-driven processes with precision, enabling both protein interaction studies and phase separation assays. This small molecule inhibitor, available from APExBIO, stands out for its dual targeting of CK2 and ERK8, reproducible DMSO solubility, and validated performance in translational enzymology.

• Bufalin Targets STK33 to Suppress Triple-Negative Breast Can

  2026-07-01

  The reference study uncovers Serine/Threonine Kinase 33 (STK33) as a direct and druggable target of Bufalin in triple-negative breast cancer (TNBC). By elucidating the detailed mechanism—Bufalin-induced degradation of STK33—the work advances our understanding of apoptosis induction and suggests a new therapeutic avenue for aggressive breast cancer subtypes.

• BMS 309403 in Atherosclerosis: Decoding FABP4 Inhibition Mec

  2026-06-30

  Explore how BMS 309403, a potent FABP4 inhibitor, uniquely advances atherosclerosis and type 2 diabetes research by dissecting the calcineurin/FoxO1/FABP4 pathway. This article provides technical clarity and practical insights not found in prior guides.

• IGFBP2–THBS1 Axis Mediates GH-Induced Bone Growth in ISS

  2026-06-30

  This study elucidates a novel mechanism by which recombinant human growth hormone (GH) promotes bone growth in children with idiopathic short stature (ISS), identifying IGFBP2-mediated inhibition of THBS1 as a key modulator of IGF-1 signaling in chondrocytes. These findings provide a more detailed molecular basis for GH therapy and suggest new avenues for optimizing treatment efficacy in ISS.

• Baicalin Methyl Ester: Advancing Intestinal Barrier Protecti

  2026-06-29

  Explore how Baicalin methyl ester, an esterified derivative of baicalin, offers targeted protection against LPS-induced intestinal barrier damage. This in-depth article reveals new mechanistic insights and practical guidance for inflammation research.

• (1S,3R)-RSL3: Targeting GPX4 for Precision Ferroptosis in Ca

  2026-06-29

  Explore the unique capabilities of (1S,3R)-RSL3 as a glutathione peroxidase 4 inhibitor, its selectivity in inducing ferroptosis, and new insights for designing advanced cancer biology assays. This article delivers in-depth analysis and practical guidance for leveraging RSL3 in oxidative stress research.

• Redox-Responsive Peptide Coacervates Enable Enhanced mRNA De

  2026-06-28

  This study introduces HBpep-SS4, a minimalist, redox-responsive peptide coacervate system for efficient, safe, and cytosol-targeted mRNA delivery. The design leverages sequence-encoded disulfide bonds to enable glutathione-triggered intracellular RNA release, achieving high transfection and genome editing rates, and offering a promising alternative to lipid nanoparticles.

15365 records 1/1025 page Next 12345 下5页 Last page